What does SUSAR stand for?

Prepare for the ICH Good Clinical Practice (GCP) Exam for Certified Clinical Research Coordinator with engaging multiple-choice questions and detailed explanations. Elevate your understanding and expertise to excel in your certification exam!

Multiple Choice

What does SUSAR stand for?

Explanation:
Suspected Unexpected Serious Adverse Reaction is the term used to classify a certain safety signal in clinical trials. It describes an adverse event that is thought to be related to the investigational product (suspected), not already described in the known safety information (unexpected), and meets the criteria for seriousness (serious). In practice, it means a patient experiences a reaction that could be caused by the study drug, is not listed in the protocol or the product labeling/Investigator’s Brochure as a known adverse effect, and has outcomes such as death, life-threatening events, hospitalization, disability, or other important medical events. Because SUSARs may indicate new safety information, they require expedited reporting to sponsors and regulatory authorities and ongoing safety follow-up.

Suspected Unexpected Serious Adverse Reaction is the term used to classify a certain safety signal in clinical trials. It describes an adverse event that is thought to be related to the investigational product (suspected), not already described in the known safety information (unexpected), and meets the criteria for seriousness (serious). In practice, it means a patient experiences a reaction that could be caused by the study drug, is not listed in the protocol or the product labeling/Investigator’s Brochure as a known adverse effect, and has outcomes such as death, life-threatening events, hospitalization, disability, or other important medical events. Because SUSARs may indicate new safety information, they require expedited reporting to sponsors and regulatory authorities and ongoing safety follow-up.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy